



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
Rockville, MD 20857

August 25, 2004

**FILE COPY**

Anthony C. Celeste, President  
AAC Consulting Group  
Suite 500  
Rockville, MD 20855-2765

Dear Mr. Celeste:

Your petition requesting the Food and Drug Administration to determine whether Penthrane (methoxyflurane, liquid, 99.9%) inhalation (NDA 13-056), manufactured by Abbott Laboratories, has been voluntarily withdrawn from sale for safety or efficacy reasons was received by this office on 08/25/2004. It was assigned docket number 2004P-0379/CP1 and it was filed on 08/25/2004. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Lyle D. Jaffe  
Division of Dockets Management  
Office of Management Programs  
Office of Management

2004P-0379

ACK1